Adherence  ||| S:0 E:10 ||| JJ
to  ||| S:10 E:13 ||| TO
disease-modifying  ||| S:13 E:31 ||| JJ
therapies  ||| S:31 E:41 ||| NNS
and  ||| S:41 E:45 ||| CC
attitudes  ||| S:45 E:55 ||| NNS
regarding  ||| S:55 E:65 ||| VBG
disease  ||| S:65 E:73 ||| NN
in  ||| S:73 E:76 ||| IN
patients  ||| S:76 E:85 ||| NNS
with  ||| S:85 E:90 ||| IN
multiple  ||| S:90 E:99 ||| JJ
sclerosis  ||| S:99 E:109 ||| NN
Although  ||| S:109 E:118 ||| IN
currently  ||| S:118 E:128 ||| RB
there  ||| S:128 E:134 ||| EX
is  ||| S:134 E:137 ||| VBZ
no  ||| S:137 E:140 ||| DT
cure  ||| S:140 E:145 ||| NN
for  ||| S:145 E:149 ||| IN
MS  ||| S:149 E:152 ||| NNP
the  ||| S:152 E:156 ||| DT
course  ||| S:156 E:163 ||| NN
of  ||| S:163 E:166 ||| IN
the  ||| S:166 E:170 ||| DT
disease  ||| S:170 E:178 ||| NN
can  ||| S:178 E:182 ||| MD
be  ||| S:182 E:185 ||| VB
influenced  ||| S:185 E:196 ||| VBN
by  ||| S:196 E:199 ||| IN
disease  ||| S:199 E:207 ||| NN
modifying  ||| S:207 E:217 ||| NN
therapy  ||| S:217 E:225 ||| NN
( ||| S:225 E:226 ||| -LRB-
DMT ||| S:226 E:229 ||| NNP
) ||| S:229 E:230 ||| -RRB-
.  ||| S:230 E:232 ||| .
For  ||| S:232 E:236 ||| IN
therapy  ||| S:236 E:244 ||| NN
to  ||| S:244 E:247 ||| TO
be  ||| S:247 E:250 ||| VB
sufficiently  ||| S:250 E:263 ||| RB
efficient ||| S:263 E:272 ||| JJ
,  ||| S:272 E:274 ||| ,
it  ||| S:274 E:277 ||| PRP
is  ||| S:277 E:280 ||| VBZ
crucial  ||| S:280 E:288 ||| JJ
that  ||| S:288 E:293 ||| IN
patients  ||| S:293 E:302 ||| NNS
take  ||| S:302 E:307 ||| VBP
their  ||| S:307 E:313 ||| PRP$
medication  ||| S:313 E:324 ||| NN
regularly  ||| S:324 E:334 ||| RB
as  ||| S:334 E:337 ||| RB
prescribed ||| S:337 E:347 ||| VBN
.  ||| S:347 E:349 ||| .
Adherence  ||| S:349 E:359 ||| NNP
describes  ||| S:359 E:369 ||| VBZ
the  ||| S:369 E:373 ||| DT
extent  ||| S:373 E:380 ||| NN
to  ||| S:380 E:383 ||| TO
which  ||| S:383 E:389 ||| WDT
a  ||| S:389 E:391 ||| DT
patient  ||| S:391 E:399 ||| JJ
acts  ||| S:399 E:404 ||| NNS
in  ||| S:404 E:407 ||| IN
accordance  ||| S:407 E:418 ||| NN
with  ||| S:418 E:423 ||| IN
the  ||| S:423 E:427 ||| DT
prescribed  ||| S:427 E:438 ||| JJ
timing ||| S:438 E:444 ||| NN
,  ||| S:444 E:446 ||| ,
dosing ||| S:446 E:452 ||| NN
,  ||| S:452 E:454 ||| ,
and  ||| S:454 E:458 ||| CC
frequency  ||| S:458 E:468 ||| NN
of  ||| S:468 E:471 ||| IN
medication  ||| S:471 E:482 ||| NN
administration ||| S:482 E:496 ||| NN
.  ||| S:496 E:498 ||| .
To  ||| S:498 E:501 ||| TO
date ||| S:501 E:505 ||| NN
,  ||| S:505 E:507 ||| ,
there  ||| S:507 E:513 ||| EX
are  ||| S:513 E:517 ||| VBP
no  ||| S:517 E:520 ||| RB
known  ||| S:520 E:526 ||| VBN
data  ||| S:526 E:531 ||| NNS
about  ||| S:531 E:537 ||| IN
adherence  ||| S:537 E:547 ||| JJ
rates  ||| S:547 E:553 ||| NNS
among  ||| S:553 E:559 ||| IN
patients  ||| S:559 E:568 ||| NNS
with  ||| S:568 E:573 ||| IN
MS  ||| S:573 E:576 ||| NNP
in  ||| S:576 E:579 ||| IN
Slovenia ||| S:579 E:587 ||| NNP
.  ||| S:587 E:589 ||| .
We  ||| S:589 E:592 ||| PRP
wanted  ||| S:592 E:599 ||| VBD
to  ||| S:599 E:602 ||| TO
assess  ||| S:602 E:609 ||| VB
adherence  ||| S:609 E:619 ||| VBN
in  ||| S:619 E:622 ||| IN
patients  ||| S:622 E:631 ||| NNS
with  ||| S:631 E:636 ||| IN
MS ||| S:636 E:638 ||| NNP
,  ||| S:638 E:640 ||| ,
who  ||| S:640 E:644 ||| WP
are  ||| S:644 E:648 ||| VBP
treated  ||| S:648 E:656 ||| VBN
with  ||| S:656 E:661 ||| IN
first  ||| S:661 E:667 ||| JJ
line  ||| S:667 E:672 ||| NN
DMTs  ||| S:672 E:677 ||| NN
and  ||| S:677 E:681 ||| CC
discover  ||| S:681 E:690 ||| JJ
reasons  ||| S:690 E:698 ||| NNS
for  ||| S:698 E:702 ||| IN
non-adherence ||| S:702 E:715 ||| JJ
.  ||| S:715 E:717 ||| .
A  ||| S:717 E:719 ||| DT
number  ||| S:719 E:726 ||| NN
of  ||| S:726 E:729 ||| IN
451  ||| S:729 E:733 ||| CD
patients  ||| S:733 E:742 ||| NNS
were  ||| S:742 E:747 ||| VBD
invited  ||| S:747 E:755 ||| VBN
to  ||| S:755 E:758 ||| TO
participate ||| S:758 E:769 ||| VB
.  ||| S:769 E:771 ||| .
They  ||| S:771 E:776 ||| PRP
received  ||| S:776 E:785 ||| VBD
two  ||| S:785 E:789 ||| CD
questionnaires  ||| S:789 E:804 ||| NN
via  ||| S:804 E:808 ||| IN
post  ||| S:808 E:813 ||| NN
mail ||| S:813 E:817 ||| NN
.  ||| S:817 E:819 ||| .
The  ||| S:819 E:823 ||| DT
adherence  ||| S:823 E:833 ||| JJ
rate  ||| S:833 E:838 ||| NN
and  ||| S:838 E:842 ||| CC
putative  ||| S:842 E:851 ||| JJ
reasons  ||| S:851 E:859 ||| NNS
for  ||| S:859 E:863 ||| IN
non-adherence  ||| S:863 E:877 ||| NNP
were  ||| S:877 E:882 ||| VBD
assessed  ||| S:882 E:891 ||| VBN
by  ||| S:891 E:894 ||| IN
the  ||| S:894 E:898 ||| DT
use  ||| S:898 E:902 ||| NN
of  ||| S:902 E:905 ||| IN
standardized  ||| S:905 E:918 ||| JJ
self-report  ||| S:918 E:930 ||| JJ
Multiple  ||| S:930 E:939 ||| NNP
Sclerosis  ||| S:939 E:949 ||| NNP
Treatment  ||| S:949 E:959 ||| NNP
Experience  ||| S:959 E:970 ||| NNP
Questionnaire  ||| S:970 E:984 ||| NNP
( ||| S:984 E:985 ||| -LRB-
MSTEQ ||| S:985 E:990 ||| NNP
) ||| S:990 E:991 ||| -RRB-
.  ||| S:991 E:993 ||| .
Patients ||| S:993 E:1001 ||| NNS
'  ||| S:1001 E:1003 ||| POS
attitudes  ||| S:1003 E:1013 ||| NNS
regarding  ||| S:1013 E:1023 ||| VBG
disease ||| S:1023 E:1030 ||| NN
,  ||| S:1030 E:1032 ||| ,
therapy  ||| S:1032 E:1040 ||| NN
and  ||| S:1040 E:1044 ||| CC
relationship  ||| S:1044 E:1057 ||| NN
with  ||| S:1057 E:1062 ||| IN
their  ||| S:1062 E:1068 ||| PRP$
physician  ||| S:1068 E:1078 ||| NN
were  ||| S:1078 E:1083 ||| VBD
assessed  ||| S:1083 E:1092 ||| VBN
by  ||| S:1092 E:1095 ||| IN
another  ||| S:1095 E:1103 ||| DT
questionnaire ||| S:1103 E:1116 ||| NN
.  ||| S:1116 E:1118 ||| .
The  ||| S:1118 E:1122 ||| DT
analysis  ||| S:1122 E:1131 ||| NN
of  ||| S:1131 E:1134 ||| IN
results  ||| S:1134 E:1142 ||| NNS
included  ||| S:1142 E:1151 ||| VBD
299  ||| S:1151 E:1155 ||| CD
patients ||| S:1155 E:1163 ||| NNS
.  ||| S:1163 E:1165 ||| .
Among  ||| S:1165 E:1171 ||| IN
the  ||| S:1171 E:1175 ||| DT
patients  ||| S:1175 E:1184 ||| NNS
18.5 ||| S:1184 E:1188 ||| CD
%  ||| S:1188 E:1190 ||| NN
missed  ||| S:1190 E:1197 ||| VBN
at  ||| S:1197 E:1200 ||| IN
least  ||| S:1200 E:1206 ||| JJS
one  ||| S:1206 E:1210 ||| CD
medication  ||| S:1210 E:1221 ||| NN
dose  ||| S:1221 E:1226 ||| NN
in  ||| S:1226 E:1229 ||| IN
the  ||| S:1229 E:1233 ||| DT
past  ||| S:1233 E:1238 ||| JJ
28  ||| S:1238 E:1241 ||| CD
days ||| S:1241 E:1245 ||| NNS
.  ||| S:1245 E:1247 ||| .
Patients  ||| S:1247 E:1256 ||| NNS
taking  ||| S:1256 E:1263 ||| VBG
Avonex  ||| S:1263 E:1270 ||| NNP
were  ||| S:1270 E:1275 ||| VBD
significantly  ||| S:1275 E:1289 ||| RB
more  ||| S:1289 E:1294 ||| JJR
adherent  ||| S:1294 E:1303 ||| NNS
then  ||| S:1303 E:1308 ||| RB
patients  ||| S:1308 E:1317 ||| NNS
on  ||| S:1317 E:1320 ||| IN
other  ||| S:1320 E:1326 ||| JJ
DMTs  ||| S:1326 E:1331 ||| NN
( ||| S:1331 E:1332 ||| -LRB-
p=0.005 ||| S:1332 E:1339 ||| NNP
) ||| S:1339 E:1340 ||| -RRB-
.  ||| S:1340 E:1342 ||| .
Our  ||| S:1342 E:1346 ||| PRP$
study  ||| S:1346 E:1352 ||| NN
showed  ||| S:1352 E:1359 ||| VBD
a  ||| S:1359 E:1361 ||| DT
higher  ||| S:1361 E:1368 ||| RBR
then  ||| S:1368 E:1373 ||| RB
expected  ||| S:1373 E:1382 ||| VBN
adherence  ||| S:1382 E:1392 ||| VBN
among  ||| S:1392 E:1398 ||| IN
Slovenian  ||| S:1398 E:1408 ||| JJ
patients  ||| S:1408 E:1417 ||| NNS
with  ||| S:1417 E:1422 ||| IN
MS  ||| S:1422 E:1425 ||| NNP
( ||| S:1425 E:1426 ||| -LRB-
81.5 ||| S:1426 E:1430 ||| CD
% ||| S:1430 E:1431 ||| NN
) ||| S:1431 E:1432 ||| -RRB-
.  ||| S:1432 E:1434 ||| .
Our  ||| S:1434 E:1438 ||| PRP$
research  ||| S:1438 E:1447 ||| NN
did  ||| S:1447 E:1451 ||| VBD
not  ||| S:1451 E:1455 ||| RB
confirm  ||| S:1455 E:1463 ||| VB
the  ||| S:1463 E:1467 ||| DT
influence  ||| S:1467 E:1477 ||| NN
of  ||| S:1477 E:1480 ||| IN
side  ||| S:1480 E:1485 ||| NN
effects  ||| S:1485 E:1493 ||| NNS
or  ||| S:1493 E:1496 ||| CC
patients ||| S:1496 E:1504 ||| NNS
'  ||| S:1504 E:1506 ||| POS
attitudes  ||| S:1506 E:1516 ||| NNS
regarding  ||| S:1516 E:1526 ||| VBG
illness  ||| S:1526 E:1534 ||| NN
and  ||| S:1534 E:1538 ||| CC
therapy  ||| S:1538 E:1546 ||| NN
on  ||| S:1546 E:1549 ||| IN
adherence ||| S:1549 E:1558 ||| NN
.  ||| S:1558 E:1560 ||| .
However  ||| S:1560 E:1568 ||| RB
we  ||| S:1568 E:1571 ||| PRP
found  ||| S:1571 E:1577 ||| VBD
unexpectedly  ||| S:1577 E:1590 ||| RB
high  ||| S:1590 E:1595 ||| JJ
percentage  ||| S:1595 E:1606 ||| NN
( ||| S:1606 E:1607 ||| -LRB-
71.8 ||| S:1607 E:1611 ||| NNP
% ||| S:1611 E:1612 ||| NN
)  ||| S:1612 E:1614 ||| -RRB-
of  ||| S:1614 E:1617 ||| IN
patients  ||| S:1617 E:1626 ||| NNS
belief  ||| S:1626 E:1633 ||| NN
that  ||| S:1633 E:1638 ||| IN
psychological  ||| S:1638 E:1652 ||| JJ
factors  ||| S:1652 E:1660 ||| NNS
are  ||| S:1660 E:1664 ||| VBP
involved  ||| S:1664 E:1673 ||| VBN
in  ||| S:1673 E:1676 ||| IN
MS  ||| S:1676 E:1679 ||| NNP
aetiology ||| S:1679 E:1688 ||| NN
.  ||| S:1688 E:1690 ||| .
